Skip to main content

Table 2 Summary of published studies of CYP17 and breast cancer

From: Future possibilities in the prevention of breast cancer: Role of genetic variation in breast cancer prevention

       

CYP17 (A2/A2 versus A1/A1) and breast cancer

 
       

All cases

Advanced cases

 

Ref

Study design

Race/ethnicity

Age of patients (years)

Age of control individuals (years)

Cases (n)

Advanced cases (n)

OR

95% CI

OR

95% CI

HRT use considered?

[7*]

Nested case-control

Afro-American, Asian, Latina

63.0 ± 8.4

61.4 ± 8.3

174*

40

1.32†

0.87-2.0

2.5†

1.07-5.94

No

[16]

Case-control

White

<55

45-74

835

24

1.17

0.92-1.49

0.88†

0.38-2.01

No

[17]

Nested case-control

White

60.4 ± 11.7

60.2 ± 11.5

115

30

0.89

0.41-1.95

1.39

0.26-7.28

Yes

[18]

Case-control

Afro-American

Not given

Not given

76

21

1.40†

0.44-4.38

0.6†

0.1-4.0

No

  

Latina

  

20

7

1.93†

0.75-5.01

0.2†

0.0-1.3

 
  

White

  

27

10

0.80†

0.45-1.43

1.7†

0.6-5.1

 

[19*]

Nested case-control

White

58.3 ± 7.1‡

 

464

107

0.91

0.61-1.34

0.84†

0.54-1.32

Yes

[9*]

Case-control

Taiwanese

Not given

Not given

150

Not given

1.28

0.73-2.27

  

Yes

[20]

Case-control

White

59 (27-91)

20-44

510

93§

0.94

0.54-1.65

1.38§

0.62-3.06

No

  1. Ages are expressed as mean ± standard error, mean (range), orrange. *Total cases, not specified by ethnicity;†odds ratio (OR) reflects A1/A2 + A2/A2 combined;‡age not specified by case-control status;§advanced cases over age 55 years.